Anagenics (ASX:AN1) appoints internal CEO – The Market Herald

Subscribe

Be the first with news that moves the market

  • Health and beauty tech company Anagenics (AN1) has named its financial controller Matthew Dudek as interim CEO
  • Following the resignation of CEO and Managing Director Maria Halasz, Mr. Dudek’s new position took effect on February 28
  • Under a 12-month contract, Mr. Dudek is paid a base salary of $250,000 and during that time he and the company will determine whether a permanent CEO position is suitable.
  • The new CEO says he is honored to take on his role and looks forward to achieving key YR1 goals and leading the next stage of growth.
  • Shares are trading in gray at 4.9 cents at 2:20 p.m. AEDT

Health and beauty tech company Anagenics (AN1) has appointed its financial controller Matthew Dudek as interim CEO.

Following the resignation of CEO and Managing Director Maria Halasz, Mr. Dudek’s new position took effect on February 28.

The position is for 12 months and will see Mr. Dudek receive a base salary of $250,000 excluding pension.

During the 12 month period, he and the company can determine if a permanent CEO position is appropriate and, if so, a new contract will be put in place.

The internal appointment follows a reshuffle of the board during AN1’s ​​transition to a “digital-first” company.

With a differentiated brand base, global distribution footprint, enhanced digital platforms and a strategy that includes organic growth and acquisitions, Ms. Halasz decided it was time to step down and helped select the new CEO.

According to the company, since 2020, Mr. Dudek has played a key role in day-to-day management while serving as financial controller. He would have deep knowledge of the business and a strong track record in implementing profit improvement initiatives and strategies.

In his new role, Mr. Dudek will be supported by a senior management team that includes Chief Operating Officer, Dr. Dominic Burg, and Chief Sales Officer, Carolyn Heath.

Mr. Dudek said he was honored to take on this role.

“Anagenics is an exciting company with strong intellectual property, highly differentiated products and global potential,” he said.

“I look forward to achieving our goals and leading our next stage of growth.”

The shares were trading in gray at 4.9 cents as of 2:20 p.m. AEDT.

Shirlene J. Manley